Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Signal enhancement ratio imaging of the lung parenchyma with ultra-fast steady-state free precession MRI at 1.5T
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4683296
Author(s) Pusterla, Orso; Sommer, Gregor; Santini, Francesco; Wiese, Mark; Lardinois, Didier; Tamm, Michael; Bremerich, Jens; Bauman, Grzegorz; Bieri, Oliver
Author(s) at UniBasel Bieri, Oliver
Pusterla, Andrea Orso
Year 2018
Title Signal enhancement ratio imaging of the lung parenchyma with ultra-fast steady-state free precession MRI at 1.5T
Journal Journal of Magnetic Resonance Imaging (JMRI)
Volume 48
Number 1
Pages / Article-Number 48-57
Keywords contrast agent; lung MRI; magnetic resonance imaging; methods development; pulmonary disease; steady-state free precession
Mesh terms Adult; Aged; Artifacts; Female; Gadolinium, chemistry; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lung, diagnostic imaging; Lung Diseases, diagnostic imaging; Lung Neoplasms, diagnostic imaging; Magnetic Resonance Imaging; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive, diagnostic imaging; Pulmonary Fibrosis, diagnostic imaging; Reproducibility of Results; Respiration; Retrospective Studies; Signal Processing, Computer-Assisted; Signal-To-Noise Ratio; Technetium, chemistry; Tomography, Emission-Computed, Single-Photon
Abstract Lung perfusion MRI after i.v. gadolinium (Gd) contrast administration is commonly based on spoiled gradient-echo acquisitions, such as volume-interpolated breath-hold examinations (VIBE), suffering from low signal-to-noise in the parenchyma.; To investigate the lung signal enhancement ratio (SER) with ultra-fast steady-state free precession (ufSSFP) after Gd-administration.; Retrospective.; Ten subjects with healthy lungs; nine patients with pulmonary diseases (chronic obstructive pulmonary disease [COPD], lung cancer, pulmonary fibrosis, lung contusion).; VIBE and ufSSFP imaging of the chest was performed at 1.5T before and 3 minutes after i.v. gadobenate dimeglumine.; A workflow including deformable image registration and median filtering was used to compute 3D SER maps. SER was analyzed in the lung, blood pool, liver, muscles, and fat. The artifacts were assessed by a radiologist. In the COPD patients, ufSSFP-SER was compared to; 99m; Tc-MAA-SPECT/CT by visual scoring of lung enhancement deficits.; Mean signal, standard deviation (SD), intersubject SD, and coefficient of variation (CV) were calculated for SER. Statistical significance of differences in signal and artifacts were determined using Wilcoxon signed-rank paired test. Intermodality agreement between ufSSFP-SER and SPECT/CT was calculated by Cohen's kappa (κ; q; ).; In healthy lungs, ufSSFP-SER (99% ± 23%, mean ± pooled intrasubject SD, CV = 23%) was significantly higher (P < 10; -3; ) and more homogeneous (P < 10; -3; ) than VIBE (47% ± 26%, CV = 57%). UfSSFP-SER was significantly higher (P < 10; -3; ) for the lungs (99% ± 9%, mean ± intersubject SD) than for the blood (81% ± 7%) and other tissues (liver 33% ± 8%, muscle 26% ± 5%, fat 2% ± 1%). In the lung ufSSFP-SER exhibits homogeneity on iso-gravitational planes, and an anterior-posterior gradient. In COPD patients, ufSSFP-SER was reduced and less homogeneous compared to the control group (73% ± 33%, mean ± pooled intrasubject SD, CV = 42%). ufSSFP-SER had moderate intermodality agreement with SPECT/CT (κ; q; = 0.64).; UfSSFP-SER of the lung is a rapid and simple method. Our preliminary data show plausible results in different pulmonary diseases, motivating further evaluation in larger cohorts.; 2 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018.
Publisher Wiley
ISSN/ISBN 1053-1807 ; 1522-2586
edoc-URL https://edoc.unibas.ch/94818/
Full Text on edoc Available
Digital Object Identifier DOI 10.1002/jmri.25928
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/29297607
 
   

MCSS v5.8 PRO. 0.330 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
29/03/2024